Mandatory GRAS Notification: What FDA's Proposed Rule Would Require of Ingredient Suppliers and Brands
FDA's proposed rule would end self-affirmed GRAS. How the seven exceptions and the one-year window for existing ingredients work, and what to ask your suppliers before comments close December 9.

On August 11, FDA published a 48-page proposed rule (91 FR 51834, Docket FDA-2025-N-3262) that would require a GRAS notice for any substance a company adds to human or animal food based on its own conclusion that the substance is "generally recognized as safe." It traces back to HHS Secretary Robert F. Kennedy Jr.'s March 10, 2025 directive that FDA explore rulemaking to close the self-affirmation pathway.
Comments close December 9, 2026. This is a proposal, FDA has given no date for a final rule, and nothing about how you market an ingredient changes until one is published.
What changes, and what doesn't
Today a company can have its own experts conclude an ingredient is GRAS (the statutory exclusion from food additive premarket approval) and sell it without telling FDA. Proposed 21 CFR 170.205(a) turns "may notify" into "must notify," with a parallel change for animal food in part 570. "Food substances" here includes substances that migrate from packaging.
Three details in the text matter more than the headline:
- It is not premarket approval. FDA says a company may keep marketing a purported GRAS substance before submitting a notice, and while FDA decides whether to file it.
- Sending a notice doesn't satisfy the requirement. It is met only when FDA files the submission as a GRAS notice, after an initial review FDA proposes to finish within 45 days. If FDA later stops evaluating the notice at the notifier's request, the requirement counts as unmet.
- The consequence of not filing is priority. FDA would treat a missing notice as a factor in choosing which substances get post-market review. Our reading: the real risk is being first in line when FDA questions an ingredient, with nothing on file to defend it.
The seven exceptions
Under proposed § 170.205(b), no GRAS notice is required when:
| # | Exception | The catch |
|---|---|---|
| 1 | An FDA "no questions" letter covers the substance under its conditions of use | A changed manufacturing process, specification, use level, or food category can put you outside the letter |
| 2 | The substance is listed or affirmed as GRAS in 21 CFR parts 182, 184, or 186 | Only for the uses the regulation covers |
| 3 | Pre-1958 natural-origin nutrients under § 170.30(d), or GMP-only affirmed substances used in a similar way under § 170.30(i)(1) | Use must fit the pre-1958 or affirmed conditions |
| 4 | FDA reviewed the use through an established process, such as plant biotechnology or animal cell culture consultations, without flagging a GRAS notice | Informal technical assistance from FDA does not count |
| 5 | A threshold of regulation exemption under § 170.39 | Only the exempted use |
| 6 | An effective food contact notification (FCN) | Applies only to the manufacturer or supplier named in the FCN |
| 7 | A streamlined submission that FDA has posted on a public list | Only for uses on the market before the final rule takes effect |
Some things can't be GRAS at all, so the rule doesn't touch them: color additives, pesticide chemicals, prior-sanctioned uses, new animal drugs, and dietary ingredients in dietary supplements.
The window for ingredients already on the market
Exception 7 is the route most existing self-affirmed ingredients would take. A streamlined submission needs the submitter's name and address, the substance name, its conditions of use (foods, levels, purposes), evidence it was in interstate commerce before the effective date, and the GRN number of any earlier notice on the same use that FDA stopped evaluating. It does not require the safety data behind the GRAS conclusion.
A use that already drew an FDA "insufficient basis" letter or a not-GRAS determination can't use this route. And FDA can pull any listed use out of the exception by requiring a full notice or a food additive petition.
One provision matters for brands in particular: any person could rely on a listed submission for the same conditions of use. Your supplier's filing would cover you, as long as your use matches theirs.
The proposed timing runs from the day a final rule is published:
| Milestone | Proposed timing |
|---|---|
| Rule takes effect | 60 days after publication |
| Streamlined submissions close | 1 year after the effective date |
| Compliance date for the notice requirement | 18 months after the effective date |
Submissions would go through FDA's electronic portal (COSM) unless FDA grants a paper waiver, and any foreign-language material would need a complete English translation. Of the more than 1,200 GRAS notices FDA has filed since 1998, 617 came from foreign firms, 503 of them from countries where English is not the primary language.
FDA's own numbers
The preliminary economic analysis is where FDA sizes what it currently can't see:
- 1,028 firms hold independent (self-affirmed) GRAS conclusions, about 2,000 conclusions in total, 1,885 of them for human food.
- 1,740 substances were concluded GRAS by an association expert panel, a category FDA says includes flavors evaluated by the Flavor and Extract Manufacturers Association. FDA assumes one submission would cover all of them.
- 2,418 streamlined submissions expected, at about 32 hours each, against 180 hours for a full GRAS notice.
- $89.6 million present-value cost over 10 years at a 3 percent discount rate, roughly $10.5 million a year.
FDA also found the rule would have a significant economic impact on a substantial number of small entities, at more than 3 percent of their annual revenue. And it concedes that an insufficient-basis finding on one ingredient could shift market share and revenue to competitors whose products don't use it. FDA did not estimate the size of that effect.
Why FDA says voluntary hasn't worked
The preamble names its cases. Crude stevia leaf extracts have been on an import alert since 1991, yet FDA still issued a warning letter in 2022 over stevia leaf in green tea products. Caffeinated alcoholic beverages drew four warning letters while FDA was still reviewing one maker's GRAS notice, which that firm later asked FDA to stop evaluating. A 2022 recall of a product containing tara flour followed roughly 400 adverse event reports, and the firm never showed FDA a GRAS conclusion. Ashwagandha went on Import Alert 99-45 in 2023 without ever being the subject of a GRAS notice.
Our database shows the same system from the enforcement side. From January 2021 through August 18, 2026, we count 73 warning letters that cite an unsafe or unapproved food additive or address a firm's GRAS claim. Forty involve cannabinoids such as CBD or delta-8 THC. The rest is a scattered list: three 7-hydroxymitragynine (7-OH) sellers in mid-2025, Amanita muscaria products (Blue Forest Farms, September 2025), nicotine beverages (Nic and Jet Fuel, February 2026), partially hydrogenated oils in Greenwood Ice Cream flavors and McClure's Bakery pies, and Abbott's Similac Probiotic Supplement, where FDA called B. infantis (Bb-02) an unsafe food additive in October 2023.
Our reading: under the current system FDA finds weak GRAS conclusions one warning letter at a time, mostly for fringe substances. The proposal is aimed at mainstream ingredients whose safety dossiers sit in a supplier's files.
Supplement brands are not fully exempt
Dietary ingredients can't be GRAS, so the rule doesn't reach the actives in your supplements. It can reach the other components in the formula. FDA's 2023 warning letter to InnoMark put it plainly: when stevia is used as a sweetener rather than a dietary ingredient, "only a GRAS ingredient may be added to a dietary supplement." Our reading is that sweeteners, flavors, and similar components in supplements would fall under the new requirement, along with any functional beverage or bar in your line.
What to do before December 9
- Sort every ingredient and packaging material by its legal basis: food additive regulation, listing in parts 182, 184, or 186, a GRN with a no-questions letter, an FCN, or self-affirmed GRAS. The last group is your exposure.
- For no-questions letters, compare specs. Pull the GRN and check your supplier's process, specification, and use levels against it.
- For self-affirmed ingredients, ask the supplier in writing whether it plans a streamlined submission or a full notice, and whether any earlier notice on the substance ended in a cease-to-evaluate letter.
- For packaging covered by an FCN, confirm the material comes from the supplier named in the notification.
- Comment if the burden is real for you. FDA specifically asked about alternatives, including allowing streamlined submissions for all GRAS substances rather than only existing ones. Comments go to Docket FDA-2025-N-3262 at regulations.gov.
No reformulation is needed now. The work today is knowing which of your ingredients would need a filing, and who would file it.
Sources
- FDA, "Substances Generally Recognized as Safe," proposed rule, 91 FR 51834 (August 11, 2026), Docket FDA-2025-N-3262, RIN 0910-AJ02
- FDA warning letters to InnoMark, Inc. (September 1, 2023), Abbott Laboratories (October 24, 2023), Blue Forest Farms, LLC (September 11, 2025), and Beach Weekend Management LLC dba Nic and Jet Fuel (February 5, 2026), via the FDA Warning Letters database
Policy Canary tracks every FDA action, warning letters, recalls, guidance, and rules, against the specific products you make, by name and by ingredient. See what we would flag for your products.
Get this in your inbox every Friday.
Free FDA intelligence digest. No account required.


